They seem very good results - with good cash generation - and a good pipeline of new drugs or existing drugs being approved for new treatment types.
Guidance is carefully worded and seems underplayed for some reason........
Lets see what the market thinks!
So the market do not like the results - opens 18% down - think that is very harsh as they look very good to me (given the CV19 situation)
amazing results - shame they did not do a special dividend but we can rest assured the dividend at the year end will be impressive
So all government contracts have:
1) NDA in place during discussions and negotiations
2) Confidentiality terms included in the contract
3) Publicity terms which will mean Deepverge CANNOT do any publicity, announcements, statements, social media about the matters without getting the wording to be used approved by the government in advance.
I would imagine the civil service are not focussed upon vetting publicity requests from suppliers as an urgent need at the moment.........
Unfortunately the market seems to have expected more as we are down 5% currently (opened down 10% briefly)
All metrics are improved by around 20%+. No significant CV19 impact that I can see. The only metric down is EPS where exceptional items are included due to large exceptional item last period. EPS after exceptional items shows 20%+ growth.
Hopefully a good day today for the share price if people notice these results........
Q3 results due on 27th October
there seems to be an upward acceleration in the share price today - news? (admittedly only 2.6% up but has breached £16)
That is a difficult answer to give........
If you look at their recent RNS updates they seem to have a good pipeline of new effective treatments coming through which is positive
Total revenue is rising and margins / ROCE/ROE etc generally seem stable (move up and down c10% a year)
It is a relatively large player in the pharma space which gives it more certainty YOY
when do we think we will get news on IMUTEX? either floating off or being bought from ORPH?
Well a super gain today - but no one making any comments on here.........Glad I invested on Simon T's recommendation some time ago!
RNS - Strategic Review - Looking at options to sell all or part.........
Interesting - not clear how the share price will move now........
Venture Life on a roll
When a company with a relatively fixed cost base has the manufacturing capacity to materially increase sales, the impact on margins can be dramatic as a higher proportion of incremental revenue is converted into operating profit. That's exactly what's happening at Aim-traded Venture Life (VLG:102p), a developer, manufacturer and distributor of products for the self-care market, as its manufacturing business scales up production from both third-party contract work and brings production in-house from earnings accretive acquisitions.
The company has also been signing a raft of deals for its key brands. These include Dentyl and UltraDEX (mouthwashes, toothpastes, tooth whiteners and fresh breath beads), and the most recent acquisition, PharmaSource, a distributor of a range of medical device products (for fungal nail infections, wart removal and women's health).
Earlier this year Venture signed its largest deal to date, a 15-year agreement worth €168m (£154m) with its existing Chinese distribution partner (rights in China, Macau and Hong Kong) for Venture’s Dentyl brand (including mouthwashes, toothpastes, tooth whiteners and fresh breath beads) and other products. In the first half, the partner placed €4m of orders for Dentyl alone and contributed £2.3m to Venture’s revenue of £16.9m. The company’s like-for-like sales increased 65 per cent in the six-month period.
The company has also been launching new products including a hand sanitising gel, DISINPLUS, which has been flying off the shelfs at ASDA and at other retailers, contributing £3.2m to first half revenues. Venture has expanded the range to eight products, including anti-bacterial sprays, at minimal cost, thus providing another lucrative revenue stream for the years ahead. In the UK, Boots will launch the Dentyl range (including new products) across 800 of its key stores in November.
The impact of the eye-catching sales growth has been dramatic on Venture’s profitability. Gross profit doubled from £3.5m to almost £7m on £7.5m of incremental sales, and with operating costs only rising by £0.8m to £4m, the company’s underlying operating profit shot up to £2.3m, from break-even a year ago. Analyst Chris Donnellan at Cenkos expects full-year pre-tax profit to rise from £1.3m to £3.3m on revenue of £30.3m to produce adjusted earnings per share (EPS) of 5.3p, up from 2.2p in 2019. He has also introduced 2021 forecasts which point to pre-tax profit surging again to £4.6m on £3m higher revenue as a higher proportion of the extra gross margin earned falls to the bottom line. On this basis, expect 2021 EPS of 6p. These estimates exclude any contribution from further earnings enhancing bolt-on acquisitions. Venture has net cash of £6.6m (8p a share) to deploy and low-cost debt facilities, too.
The positive news flow explains why Venture’s shares have more than doubled in value since I outlined the investment case, at 45p, in my May 2019 Alpha Report, and are c
Yes excellent results - if you look at market cap versus assets it is almost one for one!
The downsides I see is that the dramatic growth has led to a lot of trade receivables, and a growth in inventories SO the year end cash position, whilst still positive, is down on last period. BUT both of those factors impacting cash are purely driven by the growth and will unwind in the next results as invoices are paid and the inventory levels becomes the new normal...
Would like to see a dividend but I am hoping for too much!
Should be a good day today.......easily £1. Perhaps higher IMHO. I think Simon T at IC covers so expect a positive article lunchtime further boosting SP
I think there is a lot of news flow to come which will increase the share price as the news will be driving real trading increase and value increase
To me this is just a contract win for a facility which (I think) is normally fully booked anyway
It is great news - it will raise the profile of ORPH globally BUT will it drive significant additional revenue I am not sure
I will not be selling these shares for a long time yet though